Product Name:
Lyn-ANT
Product Number:
ab-nk092-1
Target Full Name: Yes-related protein-tyrosine kinase; Tyrosine-protein kinase Lyn
Target Alias: JTK8; Kinase Lyn; KPM; Lyn; V-yes-1 Yamaguchi sarcoma viral related oncogene; FLJ26625; CCDS6162.1; ENSG00000147507
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK095-2
Antibody Target Type: Pan-specific
Protein UniProt: P07948
Protein SigNET: P07948
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Lyn sequence peptide Cat. No.: PE-01BDP80
Antibody Immunogen Sequence: CGVDLKTQPVRNTERTIYVR
Antibody Immunogen Description: Corresponds to amino acid residues G16 to R34; Post-N-terminus
Production Method: Corresponds to amino acid residues G16 to R34; Post-N-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 0.36 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 55-60 kDa.
Related Product 1: Lyn-ANT blocking peptide
Related Product 2: Lyn-pY508 phosphosite-specific antibody (Cat. No.: AB-PK688)
Related Product 3: LynSubtide - Lyn protein kinase substrate peptide
Related Product 4: CDK1 (6-20) KinSub - Cyclin-dependent kinase 1 (CDC2) (K6-K20, human) peptide; Src protein kinase substrate peptide
Scientific Background: Lyn is a protein-tyrosine kinase of the TK group and Src family. It is important in signal transduction from cell surface receptors and in the regulation of innate and adaptive immune responses and other cellular functions. Phosphorylation of T503 inhibits its phosphotransferase activity.This kinase is highly expressed and widely distributed in most tested human tissues. Lyn deficiency is involved in defects in some mast cell functions. It interacts with phosphorylated LIME1 and with CD79A upon BCR activation. Lyn is inhibited by phosphorylation at T503. It interacts with a variety of cell surface receptors on the cytoplasmic side of the plasma membrane. Lyn is biosynthetically transported to the plasma membrane via the Golgi pool of caveolin along the secretory pathway that requires its catalytic domain, but not activity. Lyn is expressed preferentially in B cells and can be bound in the plasma membrane with IgM, where it participates in antigen-mediated signal transduction. Crosslinking of membrane-bound IgM with antibody induces rapid increase in activities of Lyn and Lyn-associated PI 3-kinase. Lyn may be involved in the changes that are related to tumour pathogenesis. It is constitutively phosphorylated and activated in cells of chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) patients. Abnormally enhanced expression levels of activation of Lyn signalling can be critical in survival and proliferation of some types of cancers, inclduing breast carcinomas.